Skip to main content
Erschienen in: Pediatric Nephrology 11/2005

01.11.2005 | Original Article

Association of macrophage migration inhibitory factor −173C allele polymorphism with steroid resistance in children with nephrotic syndrome

verfasst von: Afig Berdeli, Sevgi Mir, Nese Ozkayin, Erkin Serdaroglu, Yilmaz Tabel, Alphan Cura

Erschienen in: Pediatric Nephrology | Ausgabe 11/2005

Einloggen, um Zugang zu erhalten

Abstract

The potential effects of macrophage migration inhibitory factor (MIF) on the natural immune response are due to the inhibition of immune cell activation, which is regulated by glucocorticoids. In this study, we investigated MIF −173G/C genotype and C allele frequency in 214 patients with idiopathic nephrotic syndrome (INS) and 103 healthy volunteers. We found significant increases in GC genotype (OR=3, p=0.0009) and C allele frequency (OR=2.5, p=0.0007) in INS. Upon classifying patients as steroid responsive (n=137) or resistant (n=77), a 20-fold over-expression of the CC-genotype was found in the steroid-resistant group (OR=20, p=0.0002). Moreover, a significant increase in C allele frequency in patients with focal segmental glomerulosclerosis (FSGS) has also been noted when compared with other histopathological groups (OR=3.2, p=0.0017). Furthermore, significant increases in the CC genotype (15.6% vs 3.3%) and C allele (75% vs 32%) frequencies have been found in patients with permanent renal function failure (p=0.013 and p=0.0002, respectively). Patients with the CC genotype were found to be at considerably increased risk of permanent renal failure (OR=5.43, p=0.013) and end-stage renal disease (OR=5.53, p=0.020). Additionally, there was a correlation between age of detection of proteinuria and CC genotype. We found an earlier age of onset of proteinuria in patients with the CC genotype (1.9±1.7 years) than in patients who were GC-heterozygous (3.7±3.1 years) and GG-homozygous (3.6±2.9 years, p=0.88). In summary, our results indicate that the MIF −173 C allele confers an increased risk of susceptibility to INS and plays a crucial role in glucocorticoid responsiveness.
Literatur
1.
Zurück zum Zitat Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800.CrossRefPubMed Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800.CrossRefPubMed
2.
Zurück zum Zitat Imamura K, Nishihira J, Suzuki M, Yasuda K, Sasaki S, Kusunoki Y, Tochimaru H, Takekoshi Y (1996) Identification and immunohistochemical localization of macrophage migration inhibitory factor in human glomerulonephritis. Biochem Mol Biol Int 40:1233–1242PubMed Imamura K, Nishihira J, Suzuki M, Yasuda K, Sasaki S, Kusunoki Y, Tochimaru H, Takekoshi Y (1996) Identification and immunohistochemical localization of macrophage migration inhibitory factor in human glomerulonephritis. Biochem Mol Biol Int 40:1233–1242PubMed
3.
Zurück zum Zitat Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, Metz CN, Bucala R, Atkins RC (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57:499–509PubMed Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, Metz CN, Bucala R, Atkins RC (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57:499–509PubMed
4.
Zurück zum Zitat Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage inhibitory factor. J Exp Med 179:1985–1992CrossRefPubMed Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage inhibitory factor. J Exp Med 179:1985–1992CrossRefPubMed
5.
Zurück zum Zitat Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa T, Donnelly T, Bucala R (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854CrossRefPubMed Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa T, Donnelly T, Bucala R (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854CrossRefPubMed
6.
Zurück zum Zitat Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68–71CrossRefPubMed Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68–71CrossRefPubMed
7.
Zurück zum Zitat Donn RP, Ray DW (2004) Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 182:1–9CrossRefPubMed Donn RP, Ray DW (2004) Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 182:1–9CrossRefPubMed
8.
Zurück zum Zitat Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756–759CrossRefPubMed Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756–759CrossRefPubMed
9.
Zurück zum Zitat Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46:2402–2409CrossRefPubMed Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M (2002) Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum 46:2402–2409CrossRefPubMed
10.
Zurück zum Zitat Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M, Meazza C, De Benedetti F, Thomson W, Ray D (2004) A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 50:1604–1610CrossRefPubMed Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M, Meazza C, De Benedetti F, Thomson W, Ray D (2004) A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 50:1604–1610CrossRefPubMed
11.
Zurück zum Zitat Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y,Hamanaka Y, HigakiS, Yanai H, Yoshida T, Hibi T, Okita K, Hinoda Y (2004) Association of the −173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 39:242–246CrossRefPubMed Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y,Hamanaka Y, HigakiS, Yanai H, Yoshida T, Hibi T, Okita K, Hinoda Y (2004) Association of the −173G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 39:242–246CrossRefPubMed
12.
Zurück zum Zitat Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE (2004) Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. Dermatol J Invest 123:484–487CrossRef Donn RP, Plant D, Jury F, Richards HL, Worthington J, Ray DW, Griffiths CE (2004) Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. Dermatol J Invest 123:484–487CrossRef
13.
Zurück zum Zitat Makita H, Nishimura M, Miyamoto K, Nakano T, Tanino Y, Hirokawa J, Nishihira J, Kawakami Y (1998) Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 158:573–579PubMed Makita H, Nishimura M, Miyamoto K, Nakano T, Tanino Y, Hirokawa J, Nishihira J, Kawakami Y (1998) Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 158:573–579PubMed
14.
Zurück zum Zitat Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 4:707–714PubMed Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T, Une Y, Todo S (1998) Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med 4:707–714PubMed
15.
Zurück zum Zitat Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J (1999) High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264:751–758CrossRefPubMed Shimizu T, Abe R, Nakamura H, Ohkawara A, Suzuki M, Nishihira J (1999) High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun 264:751–758CrossRefPubMed
16.
Zurück zum Zitat Lolis E (2001) Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 1:662–668CrossRefPubMed Lolis E (2001) Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 1:662–668CrossRefPubMed
17.
Zurück zum Zitat Santos L, Hall P, Metz C, Bucala R, Morand EF (2001) Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 123:309–314CrossRefPubMed Santos L, Hall P, Metz C, Bucala R, Morand EF (2001) Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 123:309–314CrossRefPubMed
18.
Zurück zum Zitat Barton A, Lamb R, Symmons D, Silman A, Thomson W, WorthingtonJ, et al (2003) Macrophage migration inhibitory factor genepolymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 4: 487–491CrossRefPubMed Barton A, Lamb R, Symmons D, Silman A, Thomson W, WorthingtonJ, et al (2003) Macrophage migration inhibitory factor genepolymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 4: 487–491CrossRefPubMed
19.
Zurück zum Zitat Sasaki S, Nishihira J, Ishibashi T, Yamasaki Y, Obikane K, Echigoya M, Sado Y, Ninomiya Y, Kobayashi K (2004) Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int. 65:469–481 Sasaki S, Nishihira J, Ishibashi T, Yamasaki Y, Obikane K, Echigoya M, Sado Y, Ninomiya Y, Kobayashi K (2004) Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int. 65:469–481
20.
Zurück zum Zitat Lan HY, Bacher M, Yang N, Mu W, Nicolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC (1997) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 185:1455–1465CrossRefPubMed Lan HY, Bacher M, Yang N, Mu W, Nicolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC (1997) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 185:1455–1465CrossRefPubMed
21.
Zurück zum Zitat Tesch CH, Nikolic-Paterson DJ, Metz CN, Mu W, Bacher M, Bucala R, Atkins RC, Lan HY (1998) Rat mesangial cells express macrophage migration inhibitory factor in vitro and in vivo. J Am Soc Nephrol 9:417–424PubMed Tesch CH, Nikolic-Paterson DJ, Metz CN, Mu W, Bacher M, Bucala R, Atkins RC, Lan HY (1998) Rat mesangial cells express macrophage migration inhibitory factor in vitro and in vivo. J Am Soc Nephrol 9:417–424PubMed
22.
Zurück zum Zitat Donn RP, Shelley E, Ollier WE, Thomson W (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785CrossRefPubMed Donn RP, Shelley E, Ollier WE, Thomson W (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44:1782–1785CrossRefPubMed
24.
Zurück zum Zitat Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM, Atkins RC (2002) Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 13:S7–S13PubMed Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM, Atkins RC (2002) Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 13:S7–S13PubMed
25.
Zurück zum Zitat De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, Lunt M, Thomson W, Ravelli A, Donn R, Martini A (2003) Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 48: 1398–407CrossRefPubMed De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, Lunt M, Thomson W, Ravelli A, Donn R, Martini A (2003) Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 48: 1398–407CrossRefPubMed
26.
Zurück zum Zitat Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4:449–460CrossRefPubMed Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (2002) Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4:449–460CrossRefPubMed
27.
Zurück zum Zitat Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, macrophage migration inhibitory factor alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1171–1176CrossRefPubMed Gregersen PK, Bucala R (2003) Macrophage migration inhibitory factor, macrophage migration inhibitory factor alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum 48:1171–1176CrossRefPubMed
28.
Zurück zum Zitat Baugh JA, Donnelly SC (2003) Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 179:15–23CrossRefPubMed Baugh JA, Donnelly SC (2003) Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 179:15–23CrossRefPubMed
29.
Zurück zum Zitat Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, Meinhardt A, Bucala R (2003) Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 162:47–56PubMed Fingerle-Rowson G, Koch P, Bikoff R, Lin X, Metz CN, Dhabhar FS, Meinhardt A, Bucala R (2003) Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 162:47–56PubMed
30.
Zurück zum Zitat Sampey AV, Hall PH, Mitchell RA, Metz CN, Morand EF (2001) Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum 44: 1273–1280CrossRefPubMed Sampey AV, Hall PH, Mitchell RA, Metz CN, Morand EF (2001) Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum 44: 1273–1280CrossRefPubMed
31.
Zurück zum Zitat Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408:211–216CrossRefPubMed Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408:211–216CrossRefPubMed
Metadaten
Titel
Association of macrophage migration inhibitory factor −173C allele polymorphism with steroid resistance in children with nephrotic syndrome
verfasst von
Afig Berdeli
Sevgi Mir
Nese Ozkayin
Erkin Serdaroglu
Yilmaz Tabel
Alphan Cura
Publikationsdatum
01.11.2005
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 11/2005
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-005-1930-9

Weitere Artikel der Ausgabe 11/2005

Pediatric Nephrology 11/2005 Zur Ausgabe

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.